The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDCC Regulatory News (DCC)

Share Price Information for DCC (DCC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5,710.00
Bid: 5,700.00
Ask: 5,705.00
Change: 0.00 (0.00%)
Spread: 5.00 (0.088%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 5,710.00
DCC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DCC Healthcare acquires Ion Laboratories

12 Nov 2019 07:00

RNS Number : 0387T
DCC PLC
12 November 2019
 

 

 

12 November 2019

 

 

DCC Healthcare announces acquisition of Ion Laboratories

 

DCC plc, the leading international sales, marketing and support services group, announces that DCC Health & Beauty Solutions has acquired Ion Laboratories, Inc ('Ion'), a provider of contract manufacturing and related services to the growing health supplements and nutritional products market in the US.

 

The acquisition of Ion follows the acquisition of Elite One Source in February 2018 and will significantly enhance DCC Health & Beauty Solutions' service offering to customers in the US market. Ion has a broad product format capability encompassing tablets, capsules, powders and liquids across a variety of product categories including herbal and botanical products, probiotics and liquid nutritionals. Ion is currently commissioning a new nutritional gummies manufacturing line which will provide DCC Health & Beauty Solutions with capability in this fast growth category. Ion's customer base largely consists of specialty brand owners and its service offering includes product development, formulation, manufacturing, packaging and regulatory services.

 

Ion's well-invested facilities in Largo, Florida extend to 350,000 square feet and provide capacity to meet its organic growth plans. The facilities comply with FDA cGMP (current Good Manufacturing Practices) and Health Canada standards and are certified by leading third-party regulatory bodies, including NSF and USDA Organic. The business is led by an experienced management team, employs 360 people and has revenues of approximately $80 million.

 

The consideration was based on an enterprise value of approximately $60 million (£46 million), most of which was paid in cash on completion.

 

 

Donal Murphy, Chief Executive of DCC plc, said today:

 

"DCC Health & Beauty Solutions provides high-quality services to leading health and beauty brand owners, specialist retailers and direct sales organisations. The acquisition of Ion significantly enhances our presence in the US market and Ion will work closely with both Elite One Source and DCC Health & Beauty Solutions' European businesses to cross-sell the full breadth of the Group's comprehensive offering for health & beauty brands.

 

The US is the world's largest health supplements and nutritional products market. It is also an innovative, high-growth market, with a fragmented contract manufacturing base. We continue to be excited by the significant opportunities for organic and acquisitive growth in this market."

 

 

 

For reference:

Donal Murphy, Chief Executive

Conor Costigan, Managing Director, DCC Healthcare

Kevin Lucey, Head of Capital Markets

 

Telephone: +353 1 2799400

Email: investorrelations@dcc.ie

Web: www.dcc.ie

 

Powerscourt (Media)

Lisa Kavanagh / Victoria Palmer-Moore

Telephone: +44 20 7250 1446

Email: DCC@powerscourt-group.com

 

About DCC plc

DCC is a leading international sales, marketing and support services group with a clear focus on performance and growth. It operates through four divisions: LPG, Retail & Oil, Technology and Healthcare.

 

DCC is an ambitious and entrepreneurial business operating in 20 countries, supplying products and services used by millions of people every day. Building strong routes to market, driving for results, focusing on cash conversion and generating superior sustainable returns on capital employed enable the Group to reinvest in its business, creating value for its stakeholders.

 

Headquartered in Dublin, employing approximately 12,700 people, DCC's four divisions are:

·; DCC LPG - a leading LPG sales and marketing business with operations in Europe, the US and Asia and a developing business in the retailing of natural gas and electricity;

·; DCC Retail & Oil - a leader in the sales, marketing and retailing of transport fuels and commercial fuels, heating oils and related products and services in Europe;

·; DCC Technology - a leading route-to-market and supply chain partner for global technology brands and customers; and

·; DCC Healthcare - a leading healthcare business, providing products and services to healthcare providers and health and beauty brand owners.

 

DCC plc is listed on the London Stock Exchange and is a constituent of the FTSE 100. In its financial year ended 31 March 2019, DCC generated revenue of £15.2 billion and operating profit of £460 million.

 

DCC has an excellent record, delivering compound annual growth of 14% in operating profit and generating an average return on capital employed of approximately 19% over 25 years as a public company.

 

 

About DCC Healthcare

DCC Healthcare is a leading healthcare business, providing products and services to healthcare providers and health and beauty brand owners. DCC Healthcare operates through two businesses, DCC Vital and DCC Health & Beauty Solutions. DCC Vital markets and sells medical and pharmaceutical products to healthcare providers across all sectors of the healthcare market in the UK and Ireland. DCC Health & Beauty Solutions builds long-term partnerships with international brand owners, providing specialist services including product development, formulation, manufacturing and packaging.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACQGGGQGGUPBGBG
Date   Source Headline
26th May 20225:41 pmRNSDirector/PDMR Shareholding
17th May 20227:00 amRNSDCC plc Investor Event Today - Leading with Energy
17th May 20227:00 amRNSResults for the year ended 31 March 2022
7th Apr 20227:00 amRNSDCC plc Upcoming Events
28th Feb 202210:44 amRNSTotal Voting Rights
15th Feb 20227:00 amRNSDCC Technology Presentation and Webcast
8th Feb 20227:00 amRNSBoard Changes
8th Feb 20227:00 amRNSInterim Management Statement
3rd Feb 202211:54 amRNSDCC Technology Presentation and Webcast
15th Dec 20217:00 amRNSDCC Management Presentation
15th Dec 20217:00 amRNSDCC plc acquires Almo Corporation
30th Nov 20214:31 pmRNSTotal Voting Rights
26th Nov 20217:15 amRNSDirector Declaration
15th Nov 20214:25 pmRNSDirector/PDMR Shareholding
11th Nov 20214:58 pmRNSDirector/PDMR Shareholding
11th Nov 202111:25 amRNSDirector/PDMR Shareholding
9th Nov 202110:01 amRNSUpdate on Timing of Interim Results Announcement
9th Nov 20217:00 amRNSBoard Changes
9th Nov 20217:00 amRNSResults for the six months ended 30 September 2021
28th Sep 20217:00 amRNSDCC Healthcare Event
14th Sep 20212:33 pmRNSDCC Healthcare Event
16th Jul 20212:17 pmRNSResult of AGM
16th Jul 20217:00 amRNSBoard Changes
16th Jul 20217:00 amRNSInterim Management Statement
13th Jul 20217:10 amRNS2021 Sustainability Report
7th Jul 20217:01 amRNSMr Cormac McCarthy
17th Jun 202112:34 pmRNS2021 Annual Report, Notice of AGM and Proxy Form
1st Jun 20217:00 amRNSTotal Voting Rights
27th May 20215:47 pmRNSDirector/PDMR Shareholding
20th May 20219:45 amRNSDirector/PDMR Shareholding
18th May 20217:00 amRNSAppointment of Chairman Designate & Board Renewal
18th May 20217:00 amRNSResults for the year ended 31 March 2021
23rd Apr 20217:14 amRNSDirector Declaration
1st Apr 20217:13 amRNSDirector Declaration
23rd Mar 20217:06 amRNSDirector Declaration
15th Mar 20217:00 amRNSDCC Healthcare acquires primary care supplier
11th Mar 20219:12 amRNSUpdate on the Migration to Euroclear Bank
26th Feb 202112:26 pmRNSTotal Voting Rights
18th Feb 20212:12 pmRNSDCC Consents to Migration of Ordinary Shares
11th Feb 20215:02 pmRNSDirector/PDMR Shareholding
4th Feb 20215:01 pmRNSDirector/PDMR Shareholding
4th Feb 20211:46 pmRNSResult of EGM
2nd Feb 20217:00 amRNSInterim Management Statement
26th Jan 20217:43 amRNSDirector Declaration
7th Jan 20214:55 pmRNSHolding in Company TR-1
7th Jan 20217:36 amRNSNotice of Extraordinary General Meeting
5th Jan 20217:00 amRNSDCC Significantly Expands Presence - US LPG market
27th Nov 20202:31 pmRNSTotal Voting Rights
18th Nov 202010:05 amRNSEnabling energy transition webcast
17th Nov 202010:16 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.